Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain. by Schuurs, ZP et al.
Computational and Structural Biotechnology Journal 19 (2021) 2806–2818journal homepage: www.elsevier .com/locate /csbjEvidence of a putative glycosaminoglycan binding site on the
glycosylated SARS-CoV-2 spike protein N-terminal domainhttps://doi.org/10.1016/j.csbj.2021.05.002
2001-0370/ 2021 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
⇑ Corresponding author.
E-mail address: neha.gandhi@qut.edu.au (N.S. Gandhi).Zachariah P. Schuurs a, Edward Hammond b, Stefano Elli c, Timothy R. Rudd d, Courtney J. Mycroft-West e,
Marcelo A. Lima e, Mark A. Skidmore e, Richard Karlsson f, Yen-Hsi Chen f, Ieva Bagdonaite f, Zhang Yang f,
Yassir A. Ahmed g, Derek J. Richard h, Jeremy Turnbull f,g, Vito Ferro i,j, Deirdre R. Coombe j, Neha S. Gandhi a,⇑
aQUT, Centre for Genomics and Personalised Health, Cancer and Ageing Research Program, School of Chemistry and Physics, Faculty of Science and Engineering, Institute of Health
and Biomedical Innovation, 2 George Street, Brisbane, QLD 4000, Australia
b Zucero Therapeutics Ltd, 1 Westlink Court, Brisbane, Queensland, Australia
c Istituto di Ricerche Chimiche e Biochimiche ‘‘G.Ronzoni”, via Giuseppe Colombo 81, 20133 Milano, Italy
dNational Institute for Biological Standards and Control, Analytical and Biological Sciences Division, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK
eMolecular & Structural Biosciences, School of Life Sciences, Keele University, Newcastle-Under-Lyme, Staffordshire ST5 5BG, UK
fCopenhagen Center for Glycomics, Department of Cellular & Molecular Medicine, University of Copenhagen, Copenhagen N 2200, Denmark
gDepartment of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 7ZB, UK
hQUT, Centre for Genomics and Personalised Health, Cancer & Ageing Research Program, Institute of Health and Biomedical Innovation at the Translational Research Institute (TRI), 37
Kent Street, Woolloongabba, Queensland 4102, Australia
i School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia
jAustralian Infectious Diseases Research Centre, The University of Queensland, Brisbane, QLD 4072, Australia
a r t i c l e i n f oArticle history:
Received 25 January 2021
Received in revised form 1 May 2021
Accepted 1 May 2021








Cosolvent MD simulationsa b s t r a c t
SARS-CoV-2 has rapidly spread throughout the world’s population since its initial discovery in 2019. The
virus infects cells via a glycosylated spike protein located on its surface. The protein primarily binds to the
angiotensin-converting enzyme-2 (ACE2) receptor, using glycosaminoglycans (GAGs) as co-receptors.
Here, we performed bioinformatics and molecular dynamics simulations of the spike protein to investi-
gate the existence of additional GAG binding sites on the receptor-binding domain (RBD), separate from
previously reported heparin-binding sites. A putative GAG binding site in the N-terminal domain (NTD) of
the protein was identified, encompassing residues 245–246. We hypothesized that GAGs of a sufficient
length might bridge the gap between this site and the PRRARS furin cleavage site, including the mutation
S247R. Docking studies using GlycoTorch Vina and subsequent MD simulations of the spike trimer in the
presence of dodecasaccharides of the GAGs heparin and heparan sulfate supported this possibility. The
heparan sulfate chain bridged the gap, binding the furin cleavage site and S247R. In contrast, the heparin
chain bound the furin cleavage site and surrounding glycosylation structures, but not S247R. These find-
ings identify a site in the spike protein that favors heparan sulfate binding that may be particularly per-
tinent for a better understanding of the recent UK and South African strains. This will also assist in future
targeted therapy programs that could include repurposing clinical heparan sulfate mimetics.
 2021 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).1. Introduction
The rapid spread of SARS coronavirus 2 (SARS-CoV-2) since its
appearance in late 2019 has elicited a swift response from the
scientific community to develop treatments and vaccines against
this virus. Effective and efficient drug discovery requires under-standing the molecular events of the virus infection pathway and
knowledge of the effects of the virus on host immunity.
SARS-CoV-2 is an enveloped positive-sense RNA virus, one of sev-
eral coronaviruses (Coronaviridae) that cause respiratory infections
in humans. Before the emergence of SARS-CoV-2, there were two
highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, which
caused severe respiratory disease in humans, and four other
human coronaviruses (HCoV-OC43, HCoV-229E, HCoV-NL63,
HCoV-HKU1) which induced mild upper respiratory disease.
SARS-CoV-2 is closely related to SARS-CoV and MERS-CoV, and, like
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patients. Although the mutation rate of SARS-CoV-2 is considered
moderate compared with other RNA viruses, numerous variants
have been recorded; some of these have mutations in the spike
(S) glycoprotein of the virus outer surface [1], the glycoprotein that
is involved in virus infection of cells. The role of the SARS-CoV-2 S
glycoprotein in virus infection makes it a key target for the devel-
opment of antiviral drugs and vaccines. Accordingly, understand-
ing how particular mutations in this glycoprotein may impact
virus infection is a key part of the drug discovery process.
The SARS-CoV-2 S glycoprotein forms homotrimers on the virus
surface where it is involved in the multistep receptor-mediated
pathway of virus-host cell adhesion and virus-host cell membrane
fusion, which culminates in cell infection. The S glycoproteins of
other Coronaviridae family members also perform this role, but
not all coronaviruses that are human pathogens recognize the
same cell surface receptor. The cell surface receptor for SARS-
CoV-2 is the human angiotensin-converting enzyme 2 (ACE2). Each
S glycoprotein monomer consists of two main functional domains
– S1 (residues 14–685) and S2 (residues 686–1273) (Fig. 1). It is
well established that the S1 subunit mediates virus attachment
to epithelial and other cell surfaces by binding to its receptor
ACE2, while the S2 subunit mediates the fusion of the viral and
human cell membranes [2,3]. Within S1, a region spanning resi-
dues 333–527 constitutes the receptor-binding domain (RBD) [4].
Cryo-EM studies revealed that the S glycoprotein trimer exists in
several different conformational states. A significant fraction of
the trimers are in a state with one of the three RBDs in an ‘‘up”
or ‘‘open” conformation, whereas other trimers had the RBDs
‘‘down” or ‘‘closed” [2,5,6]. This has the effect of either masking
(closed conformation) or exposing (open conformation) the ACE2Fig. 1. The main domains of the SARS-CoV-2 spike protein, highlighting the unique polyb
aligned SARS-CoV and MERS-CoV. Annotated domains include SP, signal peptide; NTD, N
and S2 domains; FP, fusion peptide; HR1, heptad repeat 1; CH, central helix; HR2, hepta
PDB: 6VSB and 6LZG. The up conformation of RBD is in purple; the down conformation
references to colour in this figure legend, the reader is referred to the web version of th
2807recognition interface on the RBD. The factors driving the conforma-
tional change are unclear, although a recent study suggested that
interactions of the S glycoprotein with the glycosaminoglycans
(GAGs), heparan sulfate (HS), or the structurally related heparin
(HP), could be a contributing factor [7]. Specifically, it was found
that the S glycoprotein could bind HP and ACE2 simultaneously.
Moreover, HP oligomers enhance the binding of S glycoprotein to
ACE2 [7]. Modelling studies led to the proposal that the site where
HP and HS binds on the RBD is partially obscured in the closed con-
formation but completely exposed in the open state. These findings
suggested that HP binding might increase the proportion of trimers
in an open conformation, thereby assisting ACE2 binding [7]. Data
from the same study indicated that HS side chains of cell surface
proteoglycans (HSPGs) are necessary co-factors for infection by
SARS-CoV-2, as removing cell surface HS with heparin lyases dra-
matically reduced S glycoprotein binding to cell surfaces, and
SARS-CoV-2 infection [7]. Furthermore, another study found that
whilst ACE2 is the primary receptor, the S glycoprotein can interact
with cell surfaces in the absence of ACE2, suggesting that the initial
interaction is independent of ACE2 [8].
Upon successful attachment to the cell surface, the S glycopro-
tein is cleaved by serine endoproteases at the S1/S2 site and at the
S20 site (Fig. 1). These events cause the dissociation of the S1
domain and a significant conformational change within S2, which
brings the host and viral membranes together leading to fusion
of the membrane bilayers and viral entry into the cell. This is a
mechanism common to coronaviruses [9]. For SARS-CoV-2, the
enzymes involved are believed to be the proprotein convertase,
furin, and transmembrane serine protease 2 (TMPRSS2) [10]. Inhi-
bitors of furin cleavage and TMPRSS2 cleavage have been shown to
block virus entry and suppress virus production [11,12].asic furin cleavage site that doubly functions as a GAG-binding motif, absent in the
-terminal domain; RBD, receptor binding domain; S1/S2, cleavage site between S1
d repeat 2; TM, transmembrane domain. The spike trimer structure was built from
s in cyan and red; and the PRRARS domain is in orange. (For interpretation of the
is article.)
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lyx on cell surfaces and the extracellular matrix (ECM) that
surrounds and supports cells in tissues. The ECM and a cell’s glyco-
calyx must be traversed before viruses, and infectious organisms
can engage their cell-surface receptors to mediate their entry into
cells. In addition to SARS-CoV-2, the related coronaviruses SARS-
CoV and HCoV-NL63 also use HS as attachment factors to facilitate
binding to their receptor, ACE2, and infection of cells [13–15]. Gly-
cosaminoglycans are a family of anionic carbohydrates of which HS
and HP are members. Both these GAGs are linear polysaccharides
of repeating disaccharides consisting of an N-acetylated or N-
sulfated glucosamine alternating with a uronic acid that is either
a D-glucuronic acid or an L-iduronic acid [16,17]. Each monosac-
charide in the repeating region of HP and HS may also possess
varying degrees of sulfation due to further modifications during
biosynthesis. Generally, epimerization of glucuronic acid to iduro-
nic acid is relatively low in HS, whereas for HP the reverse is true.
In HP, most disaccharides carry near complete modifications (ex-
cept of the rare 3-O-sulfate) with iduronic acid residues sulfated
at carbon-2 (2S), alternating with N-sulfated glucosamine that is
O-sulfated at carbon-6 (6S). These tri-sulfated disaccharides
account for ~70–80% of HP. In contrast, approximately ~ 50% of
HS chains are composed of unsulfated D-glucuronic acid b
(1 ? 4) N-acetylated D-glucosamine. In HS, there are also highly
sulfated regions containing tri-sulfated disaccharides, such as L-
iduronic acid (2S) a(1 ? 4) D-N-sulfoglucosamine (6S), amongst
other sulfated variants. The rare structure of 3-O-sulfated, N-
sulfated, and 6-O-sulfated glucosamine, can occur in the highly sul-
fated regions of both HS and HP [17]. The unsulfated and highly
sulfated regions of HS are typically flanked by transition regions
which consist of partially modified disaccharides separated by
completely unmodified N-acetylated domains. This domain struc-
ture is a dominant feature of HS chains that is largely lacking in
heparin chains. It is an important factor of HS-protein interactions
due to the flexibility of the non-sulfated regions. Together with
variations in their underlying disaccharide structure, HS and HP
chains also vary in length and collectively these variations in HS
and HP chains give rise to structures that are extremely heteroge-
neous. The SARS-CoV-2 spike protein displays a higher binding
affinity to certain HS or HP sulfation patterns [18]. Chain-length
and 6-O-sulfation have the greatest effect on affinity [18,19].
The S protein is heavily glycosylated, with the N-glycans
attached to it accounting for up to half of the protein’s molecular
weight. It is likely that glycosylation shields the amino acid resi-
dues and epitopes of the S protein from recognition by cells and
antibodies [2]. This probably impairs the host’s ability to raise an
adaptive immune response targeting the S protein, as generally
glycans are poor immunogens. Glycosylation may also increase
the infectivity of the virus. To date, most computational simula-
tions of the spike trimer in the presence of ligands/co-receptors
have ignored its glycosylation despite readily available information
on the glycosylation pattern [19–26]. Understanding the glycosyla-
tion pattern is crucial when developing inhibitors of a protein, as
the glycosylation chains can sterically hinder the binding of candi-
date ligands [24]. Ideally, therapies should target accessible surface
regions on the coronavirus that are highly conserved and unlikely
to mutate [27]. Hence, in this study we carried out MD simulations
that considered the glycosylation.
Most studies looking to develop treatments like antibodies
[28–30], repurposed drugs [31], GAGs [18,32,33], or fatty acid-
like molecules [34], have been targeting RBD sites within the S gly-
coprotein. However, it has been determined that mutations distal
from the RBD influence the transmissibility of SARS-CoV-2. One
mutation that has attracted interest is D614G [35]. This mutation
appears to increase viral infectivity by favoring the open RBD
conformational state, and it is now a major virus variant globally2808[36–38]. Therefore, it is astute to study new mutations that are
appearing, such as mutations to basic amino acids. One such
mutation – S247R – was documented in the first patient diagnosed
with COVID-19 in Australia (GenBank: QHR84449.1). Basic resi-
dues have a greater affinity for GAG molecules, as the negatively
charged sulfates and carboxylates of the GAG chains can interact
with the positive charges of appropriately positioned basic amino
acids [39]. The S1/S2 boundary of SARS-CoV-2 glycoprotein con-
tains a unique polybasic furin cleavage site PRRARS (681–686).
This site does not appear in SARS-CoV-1 or MERS [2] (Fig. 1) and
is one of several suggested GAG-binding motifs in the S glycopro-
tein from analyses of the amino acid sequence. Another non-RBD
HP binding sequence is located at 810–816 (SKPSKRS) [19], but this
is not exposed for binding to GAGs on monomers in either the up
or down conformations. The sequence YRLFRKS is in the RBD
domain and binds short oligosaccharides. To date, most predicted
HP binding sites are located in the RBD. These include amino acid
sequences 345–348; 354–360; 400–411; 416–426; 443–447; 453–
459; 461–468; 507–513; 517–522 and 681–686. These sites have
been published by Kim et al. [19], Mycroft-West et al. [33] and
Paiardi et al. [40].The PRRARS site is exposed, and it appears to con-
tribute to the S glycoprotein-ACE2 interaction in an auxiliary role
through electrostatic interactions and its effects on hydration
[21]. Importantly, cleavage at this site by furin or related propro-
tein convertases is essential for activating the S glycoprotein for
its role in the fusion of virus and cell membranes, thereby con-
tributing to virus production and syncytium formation [41].
Many studies have focused on the structure and function of
SARS-CoV-2-neutralizing antibodies targeting the association of
ACE2 and the S glycoprotein RBD domain [5,30,42–46]. The S gly-
coprotein can rapidly accumulate escape mutations in an experi-
mental system using a replicating VSV-SARS-CoV-2-S virus under
selection with a single antibody targeting the RBD. To avoid loss
of antibody binding affinity and drug efficacy because of mutations
in the RBD, alternatives such as using antibody cocktails as thera-
pies are being investigated [47,48]. Of particular interest are some
antibodies that have been experimentally shown to bind to non-
RBD sites of the S glycoprotein. The antibody 4A8 demonstrates
potent neutralizing activity. It binds to the NTD residues (R246,
Y145-K147, N149, K150, W152) that restrain conformational
changes (PDB: 7C2L) [49]. [49]The antibody 2G12 binds to a region
that includes the furin cleavage site but does not neutralize the
spike protein (PDB: 7L06) [50].
Understanding the dynamic structure of the S protein provides
insight into the molecular mechanisms of the protein and its recog-
nition by the host immune system, and it may reveal potential
therapeutic intervention points. Recent studies have shown hep-
arin binding to the RBD domain [33,51] and furin cleavage sites
[19]; however, binding sites appropriate for GAG oligosaccharides
longer than an octasaccharide remain elusive. Here, using struc-
tural bioinformatics methods, docking, and molecular dynamics
simulations (MD), we identified HS binding sites on the NTD of
the S protein. We then studied, in the presence of glycosylation,
the interaction of HS and HP molecules with the S247R mutant
protein, a variant of the S protein that first emerged in Melbourne,
Australia (GenBank: QHR84449.1) [52]. We propose longer GAG
molecules are able to bridge the gap between the PRRARS furin
cleavage site and the 245H-246R site with the S247R mutation
improving this binding. The emergence of specific mutations in
the S protein of UK B.1.1.7 [53] and South African B.1.351 [54] vari-
ants has caused these strains to be more virulent. How these
mutant residues contribute to virulence is not yet clear. It is possi-
ble that GAG binding to the NTD site we identified may be influ-
enced by some of these mutations and so contribute to the
virulence of these new strains. Targeting the new binding site with
antibodies or structurally tailored GAG dodecasaccharides (or
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and residues 245H-246R may prevent proteolytic cleavage at the
S1/S2 domain boundary of the S protein, thereby preventing infec-
tion of host cells.2. Material and methods
2.1. Trimer model building
A complete trimer model was built to investigate GAG oligosac-
charide binding sites. To do this, the cryo-EM structure of the tri-
meric S protein in its prefusion conformation (PDB: 6VSB [6])
was used as the base model. A homology model was built using
the SWISS-MODEL webserver [55] to account for missing loops in
the PRRARS furin cleavage site and RBD domains in the down con-
formation. The RBD domain from the RBD-ACE2 crystal structure
(PDB: 6LZG [56]) was isolated and used to replace the RBD subunit
in the up conformation from the homology model. The combined
model was merged using Modeller in UCSF Chimera v. 1.13.1
[57]. While there are now multiple trimer structures available, this
was the only trimer model structure available at the time of this
work [57].
To run simulations as close to biological conditions as possible,
glycosylations and disulfide bonds were added to the model using
the CHARMM-GUI web-server Glycan Reader & Modeler input gen-
erator [58–60]. N- and C-termini were treated as being neutral, and
disulfide bonds were added between cysteine residues 131–166,
291–301, 336–361, 379–432, 391–525, 480–488, 538–590, 617–
649, 662–671, 738–760, 743–749, 840–851, 1032–1043 and
1082–1126. Glycosylations were added according to Table S1,
adapted from the site-specific model by Grant et al. [25].2.2. Modelling of spike trimer-heparin tetrasaccharides in cosolvent
MD simulations
Cosolvent molecular dynamics (MD) simulations were carried
out on the trimeric model described above to search for new
oligosaccharide binding locations. During a cosolvent simulation,
the protein local environment and bulk are sampled to characterize
potential binding sites on the protein surface. In our experiment,
ten HP tetrasaccharides with the sequence [IdoA2S-a-(1 ? 4)-Glc
NS6S-a-(1 ? 4)]2 were used as the cosolvent. These were ran-
domly placed around the trimer model. The CHARMM-GUI input
generator [59,60] was used to place the protein at the center of a
triclinic simulation box, with 15 Å edge space. The box was sol-
vated with TIP3P water [61] and 0.15 M NaCl placed with the
Monte-Carlo method to neutralize the system charge. Long-range
electrostatics were treated using the particle-mesh Ewald (PME)
method. Periodic boundary conditions (PBC) were applied
throughout the simulations. A non-bonded cut-off of 12 Å was
used and the non-bonded neighbor list was updated at every time
step. The SHAKE algorithm [62] was used to constrain all bonds
involving hydrogen atoms. Minimization, equilibration and pro-
duction simulations were performed with GROMACS v. 2020.1
[63,64] using the CHARMM36 forcefield [65] on V100 GPU of the
NCI Gadi supercomputer. The system was first minimized for
5,000 steps followed by equilibration for 10 ns with 2 fs steps.
The final production simulation was run for 300 ns, saving a snap-
shot each 10 ps. Temperature coupling was at 303.15 K and used
the Nose-Hoover extended ensemble. Pressure coupling used the
Parrinello-Rahman extended ensemble at 1 bar. The final snapshot
was analyzed using VMD v. 1.9.3 [66] to determine the locations on
the trimer where HP molecules bound. To confirm the results, a
second simulation on the same system was conducted for 100 ns
starting with different velocities, and a third saturated system with280920 HP tetrasaccharides was built and run for 100 ns with the same
settings as described above.
2.3. HS and HP ligand docking and MD simulation to S glycoprotein
monomer
It is understood that HP favors binding to basic residues. This
rationalized a search for mutations involving basic residues that
have appeared within global SARS-CoV-2 spike amino acid
sequences. The sequences published on the COVID-19 Viral Gen-
ome Analysis Pipeline were searched for the site mutations. This
database has been assembled using data from the Global Initiative
on Sharing Avian Influenza Data (GISAID) database [67].
The initial cosolvent simulations formed the rationale behind
the docking and subsequent experiments to test the binding of
longer HS to the PRRARS site and S247R. To achieve this, the mono-
mer in the up conformation was isolated from the model. We used
USCF Chimera v. 1.13.1 [57] to mutate Ser-247 to Arg-247 and built
two systems with the HP and HS dodecasaccharides. GlycoTorch
Vina [68] was used to perform docking of oligosaccharides. The
dodecasaccharide HP ([IdoA2S-a-(1 ? 4)-GlcNS6S-a-(1 ? 4)]6)
and HS ([IdoA2S-a-(1 ? 4)-GlcNS6S-a-(1 ? 4)]2-[IdoA-a-(1 ? 4)-
GlcNAc-a-(1 ? 4)]2-[IdoA2S-a-(1 ? 4)-GlcNS6S-a-(1 ? 4)]2 were
built using the Glycam GAG builder [69], with the IdoA2S residues
considered in the 1C4 conformation. The online GlycoTorch tool
was used to convert the PDB input files to PDBQT. This tool
accounts for / and w glycosidic torsions, and contains parameters
to model 2S0 and 1C4 for iduronic/glucuronic acids [68]. All sulfate
and hydroxyl groups, and glycosidic torsion angles were treated as
flexible. The box size was 60, 53, 80 centered between the furin
cleavage domain and S247R. For docking we used an energy range
of 12, an exhaustiveness of 12, chi_cutoff = 1, chi_coeff = 2 and set
the number of modes to 100.
The two systems of the S247R S protein monomer with HP and
HS dodecasaccharides were prepared for MD simulations using the
CHARMM glycan input generator according to the same settings
outlined in 2.2. The MD simulations were performed with GRO-
MACS for 100 ns using the methodology as described in section
2.2 above. Due to the computational resources available, only a sin-
gle MD run was conducted.
2.4. ClusPro Docking
To confirm the MD simulation results, ClusPro [70] was used to
dock heparin to an unglycosylated monomer subunit of the S pro-
tein in the ‘‘up” conformation and with the S247R mutation. This
was to confirm the binding sites observed in the MD simulation
described in section 2.3. The resulting models were superimposed,
visualized and atom contacts determined using ChimeraX version
1.1 [71] (Fig. S2).
2.5. Statistical analysis of heparin-binding motifs
The putative GAG binding sequence within the SARS-CoV-2
NTD were analyzed by methods described in Rudd et al. [72]. A
brief description of the method follows. In summary, 776 heparin
binding proteins, were fragmented into sequences of a minimium
of 3 residues with at least one basic amino acid in the following
combinations; BXA, BXS, BXP, BXAS, BXAP and BXPS (where, B = ba-
sic, X = hydrophobic, A = acidic, P = polar and S = special). A com-
parison of these sequences was made with a metric using the
Levenshtein distance. This is a measure of similarity between char-
acter strings based on the minimum number of insertions, dele-
tions or substitutions that a string needs to undergo to alter one
amino acid sequence to match the other. Sequences with a similar-
ity score of greater than 0.7 (70% similarity) were considered
highly conserved. Using this same Levenshtein similarity cut-off
Z.P. Schuurs, E. Hammond, S. Elli et al. Computational and Structural Biotechnology Journal 19 (2021) 2806–2818of 0.7, sets of highly conserved basic amino acid containing
sequences extracted from heparin binding proteins were used to
support the validity of the proposed binding site in the SARS-
CoV-2 S247R mutant S protein NTD.
2.6. Trajectory, MM/PBSA analysis and electrostatic potential surface
Tools built into GROMACS were used to process the trajectories,
including re-centering, fitting, periodicity treatments and concate-
nation before analyzing them with an array of tools. MDAnalysis
[73], VMD 1.9.3 [66] and USCF Chimera [57] were used to visualize
and analyze the output trajectories. The final 50 ns of the HS and
HP trajectories was used to calculate per-residue energy decompo-
sitions with the g_mmpbsa [74] module compatible with GRO-
MACS distribution. A frame was extracted every 250 ps from
each system and a total of 200 frames were used for the MM/PBSA
calculations. The system enthalpy is calculated using the molecular
mechanics method (MM). The polar part of the solvent effect is
obtained by solving the finite difference Poisson-Boltzmann (PB)
equation, and the non-polar part is fitted by estimating the surface
area that is solvent-accessible (SA). This is demonstrated in Equa-
tion (1):
DGbind ¼ DEMM þ DGsol  TDS ð1ÞFig. 2. Multiple sequence alignment using Clustal Omega of the RBD of related virus stra
colored according to hydrophobicity in Jalview [101]. Bat, mink, and pangolin strains w
zoonotic hosts of the viruses [80,81].
2810The binding free energy is DGbind, and the intramolecular energy
under vacuum is represented by DEMM . The solvation free energy
difference is DGsol, which is the sum of polar and non-polar solva-
tion free energies. T is the absolute temperature and DS is the
change in entropy of the system. We did not carry an out entropy
calculations owing to the size of the systems. CHARMM radii were
used and an ionic strength of 0.15 M was set for the salt. The outer
dielectric constant was set to 80, and solute dielectric constant set
to 2. Further details of the MM/PBSA methods have been published
by Genheden and Ryde [75].
The electrostatic potential surface was visualized by preparing
files with PDB2PQR webserver [76]. The CHARMM forcefield, with
an internal dielectric constant of 2 and a constant of 80 for water
was used to map the potential on the DelPhi web server [77,78],
using an internal dielectric constant of 2. ChimeraX version 1.1
[79] was used to visualize the electric potential surface.2.7. Differential scanning fluorimetry
Differential scanning fluorimetry (DSF) was conducted on 1 lg
S1 in PBS (pH 7.6) with 1.25 X SYPROTM Orange (Invitrogen) in
the presence of 100 lg of either unfractionated porcine mucosal
heparin (UFH; Celsus) or size defined heparin oligosaccharidesins. Heparin binding sites identified in previous papers [19,33] are highlighted and
ere compared to the human coronaviruses, as these species are theorized to be the
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were made up to a volume of 40 lL, in 96-well qPCR plates (AB
Biosystems) before being subjected to DSF using an AB Biosystems,
StepOnePlus, qPCR machine with the TAMRA filter employed. Melt
curve experiments were performed by increasing the temperature
from 25 C to 90 C by 0.5 C increments every 30 s. Following,
smoothing (Savitxky-Golay, 2nd-order polynomial, 9 neighbors)
the first differential of the melt curves was calculated (Prism 8;
GraphPad) and the peaks used to determine the melt temperature
(Tm) of S1 alone or in the presence of UFH or size defined oligosac-
charides (MatLab software; R20018a, MathWorks).3. Results and discussion
It has been reported that the interaction of HS with SARS-CoV-2
is a requirement for the virus to infect cells [7]. The key binding
sites on the S protein reported in this earlier study were all located
in the RBD domain near the ACE2 binding site. Studies investigat-
ing where HP binds to the spike protein have predicted multiple
binding sites on the RBD [19,33,40]. The RBD protein sequence of
several coronavirus strains theorized to be zoonotically related to
SARS-CoV-2 [80,81] were aligned to allow the amino acid
sequences of these predicted HP binding sites to be compared. This
alignment (Fig. 2) revealed relative conservation of the HP binding
sites between viral strains examined. To further understand HS
interactions with the SARS-CoV-2 S trimer, we first conducted an
unbiased molecular dynamics (MD) simulation of a glycosylated
SARS-CoV-2 S trimer with ten HP tetrasaccharides randomly
placed around the protein. Such cosolvent MD simulations have lit-
erature precedence to detect novel binding sites [82]. Other pub-
lished computational studies (using CHARMM [83], or GlycamFig. 3. A representative snapshot showing the binding of heparin tetrasaccharides
to the glycosylated SARS-CoV-2 S protein, obtained from the unbiased MD
simulations. The tan ribbons are the representation of the protein; the glycosyla-
tions are the spheres coloured.
2811[25] force fields) looked at glycosylation patterns that included
N- and O-linked glycoforms [83] and glycoforms in the Golgi prior
to enzymatic modification [25], but for the purposes of this study
we considered the model used in MD simulations by Grant et al.
[25]. In our study, seven of the ten HP tetrasaccharides bound to
the trimer during the initial MD simulation (Fig. 3). Regions where
the HP tetrasaccharides bound to the protein contained the posi-
tively charged residues arginine (R246, 249, 577, 634, 682, 683,
685), lysine (K147, 150, 444), and a protonated histidine (H245),
as well as the polar uncharged serine (S71), and the small non-
polar residues glycine (G72) and alanine (A684). Two further short
cosolvent simulations (100 ns) produced the same results, provid-
ing good evidence for the binding of HP tetrasaccharides to R246
and the PRRARS domain (Fig. S1). These regions in the S1 NTD give
access to the tetrasaccharides to the protein surface between the
glycosylation sites.
A common method to provide support to data from MD simula-
tions of GAGs binding to a protein is to dock a generic HP tetramer
using the online server ClusPro [70]. We docked heparin to the
unglycosylated S247R monomer in the ‘‘up” conformation. HP
molecules bound to R246-S247R and the furin cleavage site
(Fig. S2). This aligns with the results we observed in the MD simu-
lations of the trimer and monomer.
Interestingly, a few of the amino acid residues found to interact
with HS in the MD simulations are insertions in the regions 72–82,
144–147 and 244–246, which are shared by SARS-CoV-2 and the
bat coronavirus RatG13, but not SARS-CoV. Moreover, these
regions are known to play a role in host receptor binding [85–
86]. Hence, we predict they play a significant role in controlling
the binding of SARS-CoV-2 to cells, including the process affecting
the conformation of the RBD binding site.
With mutations to the spike appearing as the pandemic spreads
across the globe, we felt it was pertinent to investigate some of
these changes because newly arising basic mutations may promote
GAG binding. Of particular interest was the S247R mutation, which
is physically located close to the PRRARS furin cleavage site and
close to some of the deletions in the UK mutant strain (B.1.1.7)
(Table S5). The S247R mutation is adjacent to two charged amino
acids (H245-R246) that have been targeted by neutralizing anti-
bodies [49]. We hypothesized that the S247R mutation would aug-
ment the basic nature of this region containing H245-R246 and
favor bridging of GAG molecules between this region and the furin
cleavage site. The GAG docking program GlycoTorch Vina [68] was
used to test this hypothesis, with HS and HP of different lengths
being examined. This determined that GAGs 12 saccharides long,
i.e. dodecasaccharides, would bridge the gap in a biased docking
(Fig. 4B). An analysis of the electrostatic surface potential
(Fig. 4A) revealed that the region HS binds is positively charged.
As predicted, the positive region near the H245-R246 is made more
basic by the S247R mutation, and this facilitated HS binding.
Using GROMACS [63,64], we ran MD simulations with the HS
and HP dodecasaccharides to conduct an in depth analysis of the
binding to the mutated site, S247R, and the PRRARS furin cleavage
site. Fig. 4B (HS) and C (HP) show a clear differentiation between
the binding modes of the two GAG molecules. Only HS bridges
the gap between the furin site and S247R, while HP sits in the
pocket between the PRRARS loop and the loop containing R634.
The less sulfated HS spans several domains, while HP has limited
contact with the S protein as indicated by the distance between
residue centers of mass (Fig. S3) according to calculations using
MDAnalysis [73,87]. This analysis also highlighted the residues
that appeared to play key roles in binding the oligosaccharides.
The distances between the centers of mass are indicative of elec-
trostatic interactions, such as hydrogen bonding, between the
atoms involved. The data in Fig. S3 supports previously published
data [18] that variation in the sulfation levels of molecules has a
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quite heterogeneous [88], with functional studies suggesting it reg-
ulates signaling proteins involved in lung development, homeosta-
sis and injury [89]. Given our data, it would be interesting to model
the interactions of specific HS structures known to be present in
the lung with the S protein to examine whether these structures
bind in the way suggested in our model, and so link the furin cleav-
age site with the region around S247R or H245-R246.
Analysis of the hydrogen bonds formed between the S protein
and the two ligands (HS and HP) revealed that glycans on the S pro-
tein are involved in binding the HP molecule (Fig. 5). Both HS and
HP bind to the PRRARS furin site and interact with R634 (Tables S2Fig. 4. (A) Electrostatic potential surface representation of the spike monomer, calculated
the PRRARS furin cleavage site and 245H-S247R site, while the right hand side is the oppo
and the (C) HP dodecasaccharides bound to the S protein in the up conformation. The sp
interpretation of the references to colour in this figure legend, the reader is referred to
2812and S3). They otherwise differently bind to the S protein: HS
bridges the gap between the PRRARS domain and S247R and does
not have any strong interactions with the glycan shield, whereas
the N-glycans near the furin cleavage site exert a shielding effect
on the short HP dodecasaccharide examined here. Longer HP
chains ignore this effect, forming a bridge between RBD heparin
binding residues (T345, R346, N354, R355, N360) and the furin
cleavage site [40]. This supports the use of UFH and longer heparin
chains over LMWH for preventing the binding of SAR-CoV-2 to the
cell surface. The higher sulfation density of the HP molecule shifts
the preferred binding of this molecule to the PRRARS furin cleavage
site and surrounding N-glycans. Compare this to the sulfates of theusing the DelPhi web-server [77,78]. The left hand side presents the face containing
site face. Representative snapshots obtained from MD frames at 100 ns of the (B) HS
heres represent glycosylations and the GAG oligosaccharides as green spheres. (For
the web version of this article.)
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chain, giving rise to a binding mode involving both the furin site
and binding to the distal 245H-S247R site. Post-MM/PBSA analysis
of the complexes support this (Fig. 6A). In Fig. 6A, HS shows a
strong affinity for residues H66 and H69; interestingly H69 is
deleted in the recent UK strain (B.1.1.7). Those two histidines are
unique in the decomposition as only HS had an effect on them.
The residues H66, H69, K77, R78, R246, R247, R634, R646, R682,
R683 and R685 were calculated to demonstrate favorable free
energy contributions to HS binding, whilst the eight arginines in
this list and K77 were found to have favorable free energy for bind-
ing to HP (Fig. 6). We believe these differences are a result of a
higher flexibility in the non-sulfated region of the HS molecule,
compared to the more fully sulfated HP. It is this flexibility thatFig. 5. Frames from 100 ns of MD simulations. Hydrogen bonds (solid cyan lines) betwe
PRRARS site is in orange, and the 247H-S247R is in green. (A) shows the surface binding
Later frames show further binding of PRRARS domain residues. Other residues binding
between the HP molecule and the S protein or glycan shield. Here the residues R683 and
saccharides from the glycan shield. Full information on the hydrogen bonds includin
interpretation of the references to colour in this figure legend, the reader is referred to
Fig. 6. MM/PBSA-binding free energy per residue decomposition [DG kcal/mol] for the pr
the protein or GAG. The residues displayed were selected as they were the ones with the l
the S glycoprotein residues 60–80B) decomposition of the S glycoprotein residues 240–2
the HP and HS ligands.
2813allows the bridging of the two regions (furin cleavage site and
the 245H-S247R region), in a manner similar to what was observed
in the studies by Perkins [90] and Rashid [91].
A graph showing the decomposition of glycosylations interact-
ing with the ligands is presented in Fig. S4. The figure indicates that
the glycosylations on the S protein interact with the HP molecule
more than the HS. Specifically, D-mannose and N-
acetylgalactosamine (Table S3) glycan subunits attached to N61
and N616. In our simulation, the glycosylations attached to these
residues formed hydrogen bonds with the HP dodecasaccharide.
Previous experimental molecular dynamics simulations have eval-
uated the effects of N-linked glycosylation on serpins and the con-
sequences of heparin binding to both proteases function and
dynamics [92–94]. Similarly, our work alludes to a role that theseen residues of the S protein or glycan shield (spheres) and the GAG molecules. The
of the HS molecule to the S247R mutation and residue R683 of the PRRARS domain.
the HS molecule include H69, S71, A262 and R634. (B) shows the hydrogen bonds
R685 of the PRRARS domain form hydrogen bonds. Other residues include R634 and
g residue, atom and distance information are in Table S2 (HS) and S3 (HP). (For
the web version of this article.)
otein–ligand interactions. The x-axis of each is numbered according to the residue in
argest affinity for the HP/HS, and were therefore of interest. A) the decomposition of
70; C) decomposition of the S glycoprotein residues 630–690; D) decomposition of
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alludes to a role that these glycosylations might play in contribut-
ing to GAG specificity.
The differences in the binding of HS and HP highlighted in this
present study is in accordance with the results of other studies that
indicate more favorable binding to certain lengths and sulfation
levels of GAGs [18]. Post-MM/PBSA analysis of the HP- and the
HS-S glycoprotein complexes revealed the relative free binding
energy and standard deviation of that average to be 461.91 ± 3.
97 kcal/mol for the HP complex and 788.39 ± 3.06 kcal/mol for
the HS complex.
A key aspect in our approach to identifying novel binding
sites on the S glycoprotein is the consideration of the site-
specific glycan shield in the MD simulations. This revealed sig-
nificant interactions between the docked GAG molecules and
the glycan side chains, which would not be apparent if these
studies had been performed in the absence of S protein glycosy-
lation. In light of this, we were able to identify a gap in the gly-
can shield at 245H-S247R that may imply an increased viral
infectivity of the S247R mutant. At the same time, this new virus
strain is likely to bind HS more strongly than the wild type
strain. Therefore, its sequestration to the cell surface by proteo-
glycans like syndecans could be vulnerable to inhibition of by
free HS chains or HS fragments. A search of the COVID-19 Viral
Genome Analysis Pipeline database revealed other sites of muta-
tion to basic residues. Table S4 shows the number of times such
mutations have been recorded. It may be pertinent to investigate
these mutations as they could promote the ability of SARS-CoV-2
to bind to cell surfaces, thus increasing virulence. These basic
mutations could also act as alternative targets for the develop-
ment of HP-based therapies. The UK strain B.1.1.7 that is spread-
ing rapidly throughout the UK has a deletion in the NTD at
residues 69–70. This is an escape mutation that is believed to
have arisen as a result of a treatment regime – in this case, con-
valescent plasma [95,96]. Our data identified H69 and S71 to be
HS binding residues (Table S1). We have included a commentary
of the amino acid residue mutations and their likely roles in HS/
HP binding that have occurred in the recent British (B.1.17) and
South African (B.1.351) mutant strains of SARS-CoV-2 (Table S5).
HS octasaccharides optimally bind to the RBD [97], but it is not
yet known where longer HS oligosaccharides bind. As a result of
our analyses, we believe they bind to the NTD, whereas the RBD
has a higher affinity for shorter oligosaccharides closer to dp8.
The thermal stability of full-length trimeric S1 was investigated
using differential scanningfluorimetry (DSF), a techniquewhichuti-
lizes a conventional real time PCR machine to determine the mid-Fig. 7. Tm of S1 with size defined oligosaccharides or heparin; H2O was used as a
control for no addition. ** Significant difference between the Tm value of S1 H2O
control (44 C ± 0.3; n = 3) compared to RBD plus dp16 (43 C ± 0; n = 3), t(4) = 5.5,
p  0.01 0. DTm = 1 C. Where no error bars are shown SD = 0.
2814point of unfolding (or melt temperature, Tm) of a given protein,
through the use of a hydrophobic fluorescent probe [98]. When
heated, protein unfolding exposes buried hydrophobic regions
where the fluorescent dye can bind. This results in an increase in flu-
orescence that can be used to produce amelt curve. The Tm can then
beobtained fromthepeakof thefirst differential. In thisway, protein
unfolding can be monitored. The Tm of full-length trimeric S1 using
this method was determined to be 44 C, approximately 2 C lower
than previously reported for the glycosylated RBD of S1 [99].
Changes in a protein’s Tm value in the presence of a ligand is
also indicative of binding affinity, therefore, the DTm of S1 with
size defined heparin oligosaccharides was determined to investi-
gate the size dependency of binding. Oligosaccharides consisting
of 16 saccharide units when mixed with S1 caused a statistically
significant 1 C reduction in the Tm of S1. Shorter oligosaccharides
consisting of 12 or 6 units did not exhibit a statistically significant
change in the Tm of S1 (Fig. 7), suggesting that heparin chains
longer than dodecamers may be required for optimal binding to
S1. It is noteworthy that UFH did not show a statistically significant
difference in Tm, thus potentially indicating that there is a limit to
the optimal length of HP that S1 can bind or that the sulfation pat-
terns present in the UFH were not optimal for binding.
A comparison of full-length S protein amino acid sequences was
made with an extensive library of amino acid sequences from
known HP binding proteins. The degree of similarity observed sug-
gests regions on the S protein that are likely to bind to GAGs. The
putative binding site at 245H-S247R did not appear with a Leven-
shtein cut-off of 0.7, but did at 0.65 (Table 1). This is because the
sequence 241–246 (LLALHR) extended by the S247R mutation
(LLALHRR) is quite rare and not conserved in the library of
heparin-binding proteins used for the analysis. The analysis also
identified that the 69–71 region is likely to be involved in HP
binding.4. Conclusions
Overall, our work shows the importance of taking into account
the glycan shield when conducting MD simulations of proteins, as
it can act to prevent binding to certain regions of the protein and
directly interact with some docked ligands. Such interactions
may be missed when conducting studies without glycosylation
being included. By considering the glycan shield, the prediction
of important sites involved in molecular interactions and possibly
immune recognition is improved. Indeed, our study identified a
putative GAG binding site at residues 241–246 of the SARS-CoV-
2 S glycoprotein. This is particularly pertinent to the South African
strain (B.1.351) mutations of this virus, with its deletion at L242-
L244. Finally, this work has confirmed the preferential affinity for
particular GAG sulfation patterns and lengths based on bridging
between different oligosaccharide binding sites that may act coop-
eratively as anchoring points to prevent or support conformational
changes in the protein. The repurposing of drugs is becoming a
common approach to developing novel therapies. This work,
among others [7], suggests the potential use against SARS-CoV-2
of HS mimetics such as Sanofi’s SR123781, which reached phase
II clinical trials (NCT00123565, NCT00338897), or PI-88 which
reached phase III trials as an anticancer agent (NCT00268593)
and has an antiviral effect against Dengue virus and flavivirus
encephalitis [100]. Future in vitro studies on the affect that HS moi-
eties have on cell infection by SARS-CoV-2 would be interesting. To
conclude, this work has revealed a putative multi-contact binding
mechanism of HS to the SARS-CoV-2 spike protein. This highlights
alternative ways that HP and HS mimetics could contribute to
treatment of COVID-19, other than preventing coagulation and
micro-thrombi formation.
Table 1
Sequence of SARS-CoV-2 S glycoprotein residues with a Levenshtein Distance above 0.7. The normalized count for similar sequences as found in the library of 776 heparin binding
proteins. The higher the normalized count, the more often a sequence was identified among the protein set. Basic amino acids are identified; arginine (blue), lysine (red) and
histidine (green). AA No; amino acid number. AA; amino acid identity. HBP; relative frequency of sequence among heparin binding proteins. The region highlighted in blue shows
residues 241–247 count with a cut-off of 0.65.
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